Trial · NCT02942264
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Phase I: Maximum Tolerated Dose (MTD) of Zotiraciclib in Combination With Dose Dense (dd) Temozolomide (TMZ) in Adult Patients With Recurrent Anaplastic Astrocytoma or Glioblastoma/Gliosarcoma | All Participants | 250 | mg/day | ||
| Phase I: Maximum Tolerated Dose (MTD) of Zotiraciclib (TG02) in Combination of Metronomic (mn) Temozolomide (TMZ) in Adult Patients With Recurrent Anaplastic Astrocytoma or Glioblastoma/Gliosarcoma | All Participants | 250 | mg/day | ||
% of Participants Free of Disease Progression at 4mos Treated w/Zotiraciclib at the Maximum Tolerated Dose in Combination Temozolomide w/Dose Dense Temozolomide Schedules in Adult Patients With Recurrent Anaplastic Astrocytoma or Glioblastoma/Gliosarcoma | All Participants | 40 | percentage of participants | ||
% of Participants Free of Disease Progression at 4mos Treated w/Zotiraciclib at the Maximum Tolerated Dose (MTD) in Combination With the Metronomic (mn) Temozolomide (TMZ) in Adult Patients With Recurrent Anaplastic Astrocytoma or Glioblastoma/Gliosarcoma | All Participants | 25 | percentage of participants | ||
| Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0) | ARM 1 Dose Level 0 - (Starting Dose) | 6 | Participants | ||
| Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0) | ARM 1 Dose Level 1 - (Dose Escalation) | 13 | Participants | ||
| Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0) | ARM 2 Dose Level 0 (Starting Dose) | 3 | Participants | ||
| Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0) | ARM 2 Dose 1 - (Dose Escalation) | 6 | Participants | ||
| Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0) | ARM 2 Dose 0 - (Dose De-escalation) | 3 | Participants | ||
| Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0) | ARM 2 Dose Level II - (Dose Escalation) | 2 | Participants | ||
| Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0) | ARM 2 Dose Level I - (Dose De-escalation) | 7 | Participants | ||
| Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0) | ARM 1 Dose Level 1 (MTD Level in ARM1) | 6 | Participants | ||
| Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0) | ARM 2 Dose Level 1 (MTD Level in ARM2) | 7 | Participants | ||
| Phase I: Number of Participants With a Dose-limiting Toxicity (DLT) | ARM 1 Dose Level 0 - (Starting Dose) | 1 | Participants | ||
| Phase I: Number of Participants With a Dose-limiting Toxicity (DLT) | ARM 1 Dose Level 1 - (Dose Escalation) | 3 | Participants | ||
| Phase I: Number of Participants With a Dose-limiting Toxicity (DLT) | ARM 2 Dose Level 0 (Starting Dose) | 0 | Participants | ||
| Phase I: Number of Participants With a Dose-limiting Toxicity (DLT) | ARM 2 Dose 1 - (Dose Escalation) | 3 | Participants | ||
| Phase I: Number of Participants With a Dose-limiting Toxicity (DLT) | ARM 2 Dose 0 - (Dose De-escalation) | 1 | Participants | ||
| Phase I: Number of Participants With a Dose-limiting Toxicity (DLT) | ARM 2 Dose Level II - (Dose Escalation) | 1 | Participants | ||
| Phase I: Number of Participants With a Dose-limiting Toxicity (DLT) | ARM 2 Dose Level I - (Dose De-escalation) | 4 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02942264/results